[COVID-19] Cell Line Development Market 2021 : Growth Potential In The Future Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec

Cell line development has wide application areas. Development of immunotherapy for the treatment of cancer is major application of cell line development. According to the World Health Organization factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Pharmaceutical and biotechnological companies are focusing on developing novel therapies such as immunotherapy due to its specificity and efficiency. Cell line development helps in speeding drug discovery process and optimization of clinical trials by providing high yield of monoclonal antibodies, which is expected to fuel growth of the cell line development market.

Cell line is a permanently established cell culture, which proliferates in fresh medium. Cell line development is utilized for examining efficiency of drug discovery and toxicity. It is essential for the production of recombinant proteins production such as, monoclonal antibodies, bi-specific monoclonal antibodies, growth factors, and enzymes using a wide variety of expression systems. Cell lines saves the crucial time, effort and cost by providing the high yield cells which can be used for in vitro testing and reduce chance of research drug to fail in clinical trial stage.

Request PDF Brochure of this report:
https://www.coherentmarketinsights.com/insight/request-pdf/1286

Increasing technological advancements in cell line development are expected to boost growth of the cell line development market. For instance, in November 2017, Lonza group launched Multiplex Cell line culture using GS Xceed Gene Expression System., which helps in testing multiple drug candidate at early developmental stage thereby saving four to six months, which otherwise is required in conventional development program.

Some of the major players operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures , Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells. These companies are entering into strategic partnership with drug discovery companies to optimize their product development:

In December 2017, Selexis SA and Turgut Pharmaceuticals announced to enter into a third commercial license agreement, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.

In April 2017, CBMG entered into a partnership with GE Healthcare for the manufacture of stem cells used in cell line development.

In January 2018, PX’Therapeutics announced collaboration with biotech firm Advaxis for process development of immunotherapies of Advaxis
In February 2018, Denali Therapeutics entered into a partnership with Lonza to develop and produce biologic medicines using the latter’s cell line development technology GS Xceed.

Industry players are focusing towards expanding business portfolio to consolidate their market position as well as increase consumer base. For instance, in February 2017, Lonza entered into strategic partnership with Sanofi, which aimed at building mammalian cell facilities to produce monoclonal antibodies in Switzerland.

Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/1286

Cell Line Development Market Taxonomy

On the basis of Product type:

Reagents & Media
Equipment
On the basis of source:

Mammalian
Non-Mammalian
On the basis of cell line:

Recombinant
Hybridomas
Continuous Cell Line
Primary Cell Line
On the basis of application:

Bioproduction
Drug Discovery
Toxicity Testing
Tissue Engineering
Research
On the basis of end user:

Pharmaceutical companies
Research and Academic Institution
On the basis of Region:

North America
Europe
Latin America
Asia Pacific
Middle East
Africa

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount for Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021:
https://www.coherentmarketinsights.com/insight/buy-now/1286

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.